Kervadec et al. 2026: Thirty Years of Ibogaine Research—Narrative Review Takeaways

Definition

Definition: Kervadec et al. (2026) in the *Journal of Clinical Psychopharmacology* (doi: 10.1097/jcp.0000000000002197) is a narrative review of human clinical literature on ibogaine/noribogaine from 1990 through February 2025. Authors include 24 studies and 38 case reports/series, conclude that current evidence is insufficient to support clinical use, note that no double-blind RCT has demonstrated efficacy for opioid use disorder (OUD), highlight high risk of bias in many positive observational reports, and emphasize cardiotoxicity from QT prolongation as a considerable risk given unproven efficacy. This synthesis is not proof of physician-supervised IV ibogaine infusion (psychoactive intravenous ibogaine). Most underlying clinical literature remains oral/observational. Ibogaine is U.S. Schedule I and not approved for any indication.

Short answer

Kervadec and colleagues’ 2026 Journal of Clinical Psychopharmacology narrative review of thirty years of human ibogaine research found insufficient evidence for clinical use, no double-blind RCT proving OUD efficacy, and serious QT-related cardiotoxicity risk. It does not validate psychoactive IV ibogaine infusion. Cardiac screening remains essential. not approved for any indication.

Why this paper matters

“Thirty years of research” is a phrase marketers weaponize. Kervadec’s actual conclusion is closer to investigational high-risk compound with inadequate controlled evidence. This article keeps that sentence intact. Companions: /blog/kock-2022-ibogaine-systematic-review, /blog/mosca-2023-ibogaine-sud-review, /blog/ibogaine-success-rate-claims.

What was studied

Methods (plain language)

Authors searched and synthesized RCTs, open-label, retrospective, and observational reports on ibogaine’s clinical use, summarizing efficacy claims and safety signals. A narrative review can organize three decades of heterogeneous literature without converting weak designs into a regulatory-grade efficacy dossier.

Key findings (no hype)

Author-facing themes:

• Most positive efficacy data come from uncontrolled, open-label, or retrospective studies—often in nonclinical settings—with high risk of bias.
• No double-blind RCT to date has demonstrated that ibogaine or noribogaine effectively treats OUD.
• Only one small RCT reported significant effects for cocaine use disorder (as framed by the review).
• Observational signals for OUD, PTSD, or polysubstance dependence remain exploratory.
• Serious adverse events are reported, especially cardiotoxicity due to QT prolongation, representing considerable risk given currently unproven efficacy.
• Authors position ibogaine as a compound of research interest that still needs better efficacy demonstration and safety optimization before psychiatric-care integration claims.

Honest reading: longevity of interest ≠ adequacy of evidence.

Limits and confounders

Route honesty: oral ≠ psychoactive IV

Kervadec maps a literature base that does not establish controlled psychoactive-IV efficacy. IV ibogaine infusion as described on this site must still be described as physician-supervised intravenous psychoactive delivery with sparse controlled IV evidence relative to oral observational series. MISTIC-type protocols remain oral ibogaine + IV magnesium support (/blog/stanford-ibogaine-mistic, /blog/ibogaine-oral-vs-iv).

Cardiac safety context

The review’s QT/cardiotoxicity emphasis aligns with:

• Knuijver 2021/2024 oral QTc + PK/PD (/blog/knuijver-2021-ibogaine-qtc-safety, /blog/knuijver-2024-ibogaine-pk-cyp2d6)
• Ona AE review (/blog/ona-2022-ibogaine-adverse-events-review)
• Brunt CV complications teaching (/blog/ibogaine-cardiovascular-complications-review)
• Mortality article (/blog/ibogaine-mortality-cardiac-risk)

Unproven efficacy + documented cardiac risk is exactly why next steps always go screening first.

What this does NOT prove for IV ibogaine infusion

U.S. Schedule I / not approved (/blog/is-ibogaine-legal-us).

How to read “exploratory PTSD/OUD signals” without cure ads

Observational symptom drops can be meaningful hypotheses and still fail under blinding, expectancy control, and long-term hard outcomes. Families should ask clinics:

1. Which controlled evidence are you citing—and for which route?
2. How do you handle QTc, electrolytes, telemetry, and rescue?
3. What aftercare exists when the “ceremony high” fades? (/blog/ibogaine-aftercare-integration)
4. Are success anecdotes labeled as anecdotes?

Relationship to other paper summaries

Next steps

If “insufficient evidence for clinical use” conflicts with aggressive clinic ads, treat that conflict as a safety signal. Learn cardiac screening at /safety-and-screening, then /apply only after informed questions. Entity: /what-is-ibogaine-infusion.

FAQ

What is the Kervadec 2026 paper? A narrative review of ~30 years of human ibogaine/noribogaine clinical literature concluding evidence is insufficient for clinical use.

Did they find a double-blind RCT proving OUD efficacy? No. Authors state no such DB RCT has demonstrated OUD efficacy.

How many studies were included? Twenty-four studies plus 38 case reports/series (as reported).

Does this prove IV ibogaine infusion works? No. It synthesizes mostly non-IV, non-pivotal evidence and warns about cardiotoxicity.

Why mention QT prolongation? Serious cardiac AEs, especially QT-related cardiotoxicity, are central given unproven efficacy.

Is observational PTSD benefit “proof”? No—review frames such signals as exploratory.

Is ibogaine approved for medical use? No. Schedule I in the U.S.

Where should families start? /safety-and-screening, then /apply if appropriate.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not approved for any indication. Our IV ibogaine programs in Mexico and Gabon are not approved U.S. clinics. Next steps: /safety-and-screening, then /apply.

Kervadec 2026 is a cautious narrative synthesis—not psychoactive IV ibogaine proof and not a cure claim.

Sources (selected)

1. Kervadec E., Bezo A., Serreau R., et al. Thirty Years of Ibogaine Research. *J Clin Psychopharmacol*. 2026;46(4):440–450. doi: 10.1097/jcp.0000000000002197.
2. Köck P. et al. *J Subst Abuse Treat*. 2022. doi: 10.1016/j.jsat.2021.108717.
3. Mosca A. et al. *Curr Neuropharmacol*. 2023. doi: 10.2174/1570159X21666221017085612.
4. Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).